KNSAKiniksa Pharmaceuticals International, plc
Price
+125%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growth steady, the market undecided.
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. ARCALYST is an interleukin-1α (“IL-1α”) and interleukin-1β (“IL-1β”) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of $214M in Q1 2026 (quarter ended Mar 31, 2026), up 56% from the same quarter a year earlier. That came with a gross margin of 90% and net income of $23M (11% of revenue). For the full year FY2025, revenue was $678M (+60% year on year) and net income $59M. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 28, 2026Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution.Earnings release · press release
- May 26, 2026On May 21, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) entered into a deed of waiver (the “Deed”) with Baker Bros. Advisors LP, on behalf of each of Baker Brothers Life Sciences, L.P. and 667, L.P. (the “Shareholders”), pursuant to which the Shareholders waived their rights to convert any of their …Material agreement entered · Form 8-K
- May 1, 2026On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the “Company”) of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 41 by RyuScore